AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Precision Radiation Oncology Article
Article Link
Cite
EndNote(RIS) BibTeX
Collect
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review | Open Access

Application of radiomics in lung immuno-oncology

Weisi Yan1 ( ), Chen Quan2, Waleed F. Mourad3, Jianda Yuan4, Zheng Shi5, Jun Yang6, Qiuxia Lu6, Jie Zhang7
Baptist Health System, Lexington, Kentucky, USA
City of Hope Comprehensive Cancer Center, Duarte, California, USA
Department of Radiation Medicine, University of Kentucky, Lexington, Kentucky, USA
Translational Oncology at Merck & Co, Kenilworth, New Jersey, USA
UMC Health System, Lubbock, Texas, USA
Foshan Chancheng Hospital, Foshan, Guangdong, China
Department of Radiology, University of Kentucky, Lexington, Kentucky, USA
Show Author Information

Abstract

Radiomics is a rapidly evolving field of research that extracts and analyzes quantitative features within medical images. Those features are termed as radiomic features that can characterize a tumor in a comprehensive and quantitative manner with regard to its internal structure and heterogeneity. Radiomic features can be used, alone or in combination with demographic, histological, genomic, or proteomic data, for predicting prognosis or treatment response. Immunotherapy, or immune-oncology, is the study of cancer treatment by taking advantage of the body's immune system to prevent, control, and eliminate cancer. In this review, we first provide a brief introduction to both radiomics and immune-oncology in lung cancer. Then, we discuss the need for developing immune-oncology biomarkers, and the advantages of radiomics in identifying biomarkers related to immunotherapy. We also discuss potential areas in and out of tumors, such as the intra-tumoral hypoxic region and tumor microenvironment, where radiomic markers might be extracted, as well as a potential application of radiomic biomarkers in clinical lung cancer management. Finally, we present radiation and immune modulation in non-small cell lung cancer, clinical trials and their design to incorporate radiomic biomarkers, and radiomics-guided precision radiation therapy.

Keywords

radiationradiomicsnon-small cell lung cancerimmune modulation

References

1

Lambin P, Rios-Velazquez E, Leijenaar R, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012;48(4):441-446.
Crossref Google Scholar
2
Aerts HJ, Velazquez ER, Leijenaar RT, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach [published correction appears in Nat Commun. 2014;5: 4644. Cavalho, Sara [corrected to Carvalho, Sara]]. Nat Commun. 2014;5:4006. Published 2014 Jun 3.
Crossref
3

Huynh E, Coroller TP, Narayan V, et al. CT-based radiomic analysis of stereotactic body radiation therapy patients with lung cancer. Radiother Oncol. 2016;120(2):258-266. doi:10.1016/j.radonc.2016.05.024
Crossref Google Scholar
4

Sun R, Limkin EJ, Vakalopoulou M, et al. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol. 2018;19(9):1180-1191.
Crossref Google Scholar
5

Coroller TP, Grossmann P, Hou Y, et al. CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma. Radiother Oncol. 2015;114(3):345-350.
Crossref Google Scholar
6

Grove O, Berglund AE, Schabath MB, et al. Quantitative computed tomographic descriptors associate tumor shape complexity and intratumor heterogeneity with prognosis in lung adenocarcinoma [published correction appears in PLoS One. 2021 Mar 8;16(3):e0248541]. PLoS ONE. 2015;10(3):e0118261. doi:10.1371/journal.pone.0118261
Crossref Google Scholar
7

Darvin P, Toor SM, Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018;50(12):1-11.
Crossref Google Scholar
8

Webster RM. The immune checkpoint inhibitors: where are we now? Nat Rev Drug Discov. 2014;13(12):883-884.
Crossref Google Scholar
9

Villegas FR, Coca S, Villarrubia VG, et al. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer. 2002;35(1):23-28.
Crossref Google Scholar
10

Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819-1830.
Crossref Google Scholar
11

Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078-2092.
Crossref Google Scholar
12

Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040-2051.
Crossref Google Scholar
13

Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19(3):133-150.
Crossref Google Scholar
14

Fujii T, Naing A, Rolfo C, Hajjar J. Biomarkers of response to immune checkpoint blockade in cancer treatment. Crit Rev Oncol Hematol. 2018;130:108-120.
Crossref Google Scholar
15

Ancevski Hunter K, Socinski MA, Villaruz LC. PD-L1 testing in guiding patient selection for pd-1/pd-l1 inhibitor therapy in lung cancer. Mol Diagn Ther. 2018;22(1):1-10.
Crossref Google Scholar
16

Aguilar EJ, Ricciuti B, Gainor JF, et al. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. Ann Oncol. 2019;30(10):1653-1659.
Crossref Google Scholar
17

Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563-567.
Crossref Google Scholar
18

Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568-571.
Crossref Google Scholar
19

Fox BA, Schendel DJ, Butterfield LH, et al. Defining the critical hurdles in cancer immunotherapy. J Transl Med. 2011;9:214.
Crossref Google Scholar
20

Ma W, Gilligan BM, Yuan J, Li T. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol. 2016;9(1):47.
Crossref Google Scholar
21

Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing [published correction appears in N Engl J Med. 2012 Sep 6;367(10):976]. N Engl J Med. 2012;366(10):883-892.
Crossref Google Scholar
22

Jamal-Hanjani M, Quezada SA, Larkin J, Swanton C. Translational implications of tumor heterogeneity. Clin Cancer Res. 2015;21(6):1258-1266.
Crossref Google Scholar
23

Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013;501(7467):338-345.
Crossref Google Scholar
24

Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res. 2012;72(19):4875-4882.
Crossref Google Scholar
25

Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012;481(7381):306-313.
Crossref Google Scholar
26

Schmitt MW, Loeb LA, Salk JJ. The influence of subclonal resistance mutations on targeted cancer therapy. Nat Rev Clin Oncol. 2016;13(6):335-347.
Crossref Google Scholar
27

Wu J, Gensheimer MF, Dong X, et al. Robust intratumor partitioning to identify high-risk subregions in lung cancer: a pilot study. Int J Radiat Oncol Biol Phys. 2016;95(5):1504-1512.
Crossref Google Scholar
28

Neri E, Del Re M, Paiar F, et al. Radiomics and liquid biopsy in oncology: the holons of systems medicine. Insights Imaging. 2018;9(6):915-924.
Crossref Google Scholar
29

Mu W, Tunali I, Gray JE, Qi J, Schabath MB, Gillies RJ. Radiomics of 18F-FDG PET/CT images predicts clinical benefit of advanced NSCLC patients to checkpoint blockade immunotherapy. Eur J Nucl Med Mol Imaging. 2020;47(5):1168-1182.
Crossref Google Scholar
30

Rizzo S, Petrella F, Buscarino V, et al. CT radiogenomic characterization of EGFR, K-RAS, and ALK mutations in non-small cell lung cancer. Eur Radiol. 2016;26(1):32-42.
Crossref Google Scholar
31

Liu Y, Kim J, Balagurunathan Y, et al. Radiomic features are associated with EGFR mutation status in lung adenocarcinomas. Clin Lung Cancer. 2016;17(5):441-448.
Crossref Google Scholar
32

Gevaert O, Echegaray S, Khuong A, et al. Predictive radiogenomics modeling of EGFR mutation status in lung cancer. Sci Rep. 2017;7:41674.
Crossref Google Scholar
33

Jia TY, Xiong JF, Li XY, et al. Identifying EGFR mutations in lung adenocarcinoma by noninvasive imaging using radiomics features and random forest modeling. Eur Radiol. 2019;29(9):4742-4750.
Crossref Google Scholar
34

Nordsmark M, Bentzen SM, Rudat V, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol. 2005;77(1):18-24.
Crossref Google Scholar
35

Le QT, Chen E, Salim A, et al. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res. 2006;12(5):1507-1514.
Crossref Google Scholar
36

Taiakina D, Dal Pra A, Bristow RG. Intratumoral hypoxia as the genesis of genetic instability and clinical prognosis in prostate cancer. Adv Exp Med Biol. 2014;772:189-204.
Crossref Google Scholar
37

Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol. 1953;26(312):638-648.
Crossref Google Scholar
38

Strese S, Fryknäs M, Larsson R, Gullbo J. Effects of hypoxia on human cancer cell line chemosensitivity. BMC Cancer. 2013;13:331.
Crossref Google Scholar
39

Scharping NE, Menk AV, Whetstone RD, Zeng X, Delgoffe GM. Efficacy of PD-1 blockade is potentiated by metformin-induced reduction of tumor hypoxia. Cancer Immunol Res. 2017;5(1):9-16.
Crossref Google Scholar
40

Hatfield SM, Kjaergaard J, Lukashev D, et al. Immunological mechanisms of the antitumor effects of supplemental oxygenation. Sci Transl Med. 2015; 7(277).
Crossref Google Scholar
41

Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol. 2007;25(26):4066-4074.
Crossref Google Scholar
42

Noman MZ, Hasmim M, Lequeux A, et al. Improving cancer immunotherapy by targeting the hypoxic tumor microenvironment: new opportunities and challenges. Cells. 2019;8(9):1083.
Crossref Google Scholar
43

Tubin S, Popper HH, Brcic L. Novel stereotactic body radiation therapy (SBRT)-based partial tumor irradiation targeting hypoxic segment of bulky tumors (SBRT-PATHY): improvement of the radiotherapy outcome by exploiting the bystander and abscopal effects. Radiat Oncol. 2019;14(1):21.
Crossref Google Scholar
44

Xu Z, Li XF, Zou H, Sun X, Shen B. 18F-Fluoromisonidazole in tumor hypoxia imaging. Oncotarget. 2017;8(55):94969-94979.
Crossref Google Scholar
45

Crispin-Ortuzar M, Apte A, Grkovski M, et al. Predicting hypoxia status using a combination of contrast-enhanced computed tomography and [18F]-Fluorodeoxyglucose positron emission tomography radiomics features. Radiother Oncol. 2018;127(1):36-42.
Crossref Google Scholar
46

Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci. 2012;125(23):5591-5596.
Crossref Google Scholar
47

Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960-1964.
Crossref Google Scholar
48

Parra ER, Behrens C, Rodriguez-Canales J, et al. Image analysis-based assessment of PD-L1 and tumor-associated immune cells density supports distinct intratumoral microenvironment groups in non-small cell lung carcinoma patients. Clin Cancer Res. 2016;22(24):6278-6289.
Crossref Google Scholar
49

Braman NM, Etesami M, Prasanna P, et al. Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI [published correction appears in Breast Cancer Res. 2017 Jul 10;19(1):80]. Breast Cancer Res. 2017;19(1):57.
Crossref Google Scholar
50

Dou TH, Coroller TP, van Griethuysen JJM, Mak RH, Aerts HJWL. Peritumoral radiomics features predict distant metastasis in locally advanced NSCLC. PLoS ONE. 2018;13(11):e0206108. doi:10.1371/journal.pone.0206108
Crossref Google Scholar
51

Yoon HJ, Kang J, Park H, Sohn I, Lee SH, Lee HY. Deciphering the tumor microenvironment through radiomics in non-small cell lung cancer: correlation with immune profiles. PLoS ONE. 2020;15(4):e0231227. doi:10.1371/journal.pone.0231227
Crossref Google Scholar
52

Louie AV, Palma DA, Dahele M, Rodrigues GB, Senan S. Management of early-stage non-small cell lung cancer using stereotactic ablative radiotherapy: controversies, insights, and changing horizons. Radiother Oncol. 2015;114(2):138-147.
Crossref Google Scholar
53

Eberhardt WE, De Ruysscher D, Weder W, et al. 2nd ESMO Consensus Conference in Lung Cancer: locally advanced Stage Ⅲ non-small-cell lung cancer. Ann Oncol. 2015;26(8):1573-1588.
Crossref Google Scholar
54

Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;5(3):288-300.
Crossref Google Scholar
55

Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627-1639.
Crossref Google Scholar
56

Shaverdian N, Lisberg AE, Bornazyan K, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial [published correction appears in Lancet Oncol. 2017 Jul;18(7):e371]. Lancet Oncol. 2017;18(7):895-903.
Crossref Google Scholar
57

Cook AM, Berry RJ. Direct and indirect effects of radiation: their relation to growth. Nature. 1966;210(5033):324-325.
Crossref Google Scholar
58

Mole RH. Whole body irradiation; radiobiology or medicine? Br J Radiol. 1953;26(305):234-241.
Crossref Google Scholar
59

Chee CA, Ilbery PL, Rickinson AB. Depression of lymphocyte replicating ability in radiotherapy patients. Br J Radiol. 1974;47(553):37-43.
Crossref Google Scholar
60

Routman DM, Garant A, Lester SC, et al. A comparison of grade 4 lymphopenia with proton versus photon radiation therapy for esophageal cancer. Adv Radiat Oncol. 2019;4(1):63-69.
Crossref Google Scholar
61

Wirsdörfer F, Jendrossek V. The role of lymphocytes in radiotherapy-induced adverse late effects in the lung. Front Immunol. 2016;7:591.
Crossref Google Scholar
62

Ladbury CJ, Rusthoven CG, Camidge DR, Kavanagh BD, Nath SK. Impact of radiation dose to the host immune system on tumor control and survival for Stage Ⅲ non-small cell lung cancer treated with definitive radiation therapy. Int J Radiat Oncol Biol Phys. 2019;105(2):346-355.
Crossref Google Scholar
63

Reits EA, Hodge JW, Herberts CA, et al. Radiation modulates the peptide repertoire, enhances MHC class Ⅰ expression, and induces successful antitumor immunotherapy. J Exp Med. 2006;203(5):1259-1271.
Crossref Google Scholar
64

Spiotto M, Fu YX, Weichselbaum RR. The intersection of radiotherapy and immunotherapy: mechanisms and clinical implications. Sci Immunol. 2016;1(3):EAAG1266.
Crossref Google Scholar
65

Schaue D, Kachikwu EL, McBride WH. Cytokines in radiobiological responses: a review. Radiat Res. 2012;178(6):505-523.
Crossref Google Scholar
66

Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol. 2005;174(12):7516-7523.
Crossref Google Scholar
67

Bang A, Wilhite TJ, Pike LRG, et al. Multicenter evaluation of the tolerability of combined treatment with PD-1 and CTLA-4 immune checkpoint inhibitors and palliative radiation therapy. Int J Radiat Oncol Biol Phys. 2017;98(2):344-351.
Crossref Google Scholar
68

Luke JJ, Lemons JM, Karrison TG, et al. Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors. J Clin Oncol. 2018;36(16):1611-1618.
Crossref Google Scholar
69

Xia WY, Feng W, Zhang CC, et al. Radiotherapy for non-small cell lung cancer in the immunotherapy era: the opportunity and challenge-a narrative review. Transl Lung Cancer Res. 2020;9(5):2120-2136.
Crossref Google Scholar
70

Yan W, Khan MK, Wu X, et al. Spatially fractionated radiation therapy: history, present and the future. Clin Transl Radiat Oncol. 2019;20:30-38.
Crossref Google Scholar
71

Kanagavelu S, Gupta S, Wu X, et al. In vivo effects of lattice radiation therapy on local and distant lung cancer: potential role of immunomodulation. Radiat Res. 2014;182(2):149-162.
Crossref Google Scholar
72

Tubin S, Ahmed MM, Gupta S. Radiation and hypoxia-induced non-targeted effects in normoxic and hypoxic conditions in human lung cancer cells. Int J Radiat Biol. 2018;94(3):199-211.
Crossref Google Scholar
73

Epel B, Maggio MC, Barth ED, et al. Oxygen-guided radiation therapy. Int J Radiat Oncol Biol Phys. 2019;103(4):977-984.
Crossref Google Scholar
74

Markovsky E, Budhu S, Samstein RM, et al. An antitumor immune response is evoked by partial-volume single-dose radiation in 2 murine models. Int J Radiat Oncol Biol Phys. 2019;103(3):697-708.
Crossref Google Scholar
75

Tubin S, Gupta S, Grusch M, et al. Shifting the immune-suppressive to predominant immune-stimulatory radiation effects by SBRT-PArtial tumor irradiation targeting HYpoxic segment (SBRT-PATHY). Cancers (Basel). 2020;13(1):50.
Crossref Google Scholar
76

Ling CC, Humm J, Larson S, et al. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys. 2000;47(3):551-560.
Crossref Google Scholar
77

Colton M, Cheadle EJ, Honeychurch J, Illidge TM. Reprogramming the tumour microenvironment by radiotherapy: implications for radiotherapy and immunotherapy combinations. Radiat Oncol. 2020;15(1):254.
Crossref Google Scholar
78

Renfro LA, Mallick H, An MW, Sargent DJ, Mandrekar SJ. Clinical trial designs incorporating predictive biomarkers. Cancer Treat Rev. 2016;43:74-82.
Crossref Google Scholar
79

Mandrekar SJ, Sargent DJ. Drug designs fulfilling the requirements of clinical trials aiming at personalizing medicine. Chin Clin Oncol. 2014;3(2):14.
Google Scholar
80

Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011;1(1):44-53.
Crossref Google Scholar
81

Kimani PK, Glimm E, Maurer W, Hutton JL, Stallard N. Practical guidelines for adaptive seamless phase Ⅱ/Ⅲ clinical trials that use Bayesian methods. Stat Med. 2012;31(19):2068-2085.
Crossref Google Scholar
82

Le-Rademacher J, Dahlberg S, Lee JJ, Adjei AA, Mandrekar SJ. Biomarker clinical trials in lung cancer: design, logistics, challenges, and practical considerations. J Thorac Oncol. 2018;13(11):1625-1637.
Crossref Google Scholar
83

Govindan R, Mandrekar SJ, Gerber DE, et al. ALCHEMIST trials: a golden opportunity to transform outcomes in early-stage non-small cell lung cancer. Clin Cancer Res. 2015;21(24):5439-5444.
Crossref Google Scholar
84

Alden RS, Mandrekar SJ, Oxnard GR. Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials. Chin Clin Oncol. 2015;4(3):37.
Google Scholar
85

Mandrekar SJ, Dahlberg SE, Simon R. Improving clinical trial efficiency: thinking outside the box. Am Soc Clin Oncol Educ Book. 2015:e141-e147.
Crossref Google Scholar
86

Bonaventura P, Shekarian T, Alcazer V, et al. Cold tumors: a therapeutic challenge for immunotherapy. Front Immunol. 2019;10:168.
Crossref Google Scholar
87

Sanmamed MF, Chen L. A paradigm shift in cancer immunotherapy: from enhancement to normalization [published correction appears in Cell. 2019 Jan 24;176(3):677]. Cell. 2018;175(2):313-326.
Crossref Google Scholar
88

DeNardo DG, Brennan DJ, Rexhepaj E, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011;1(1):54-67.
Crossref Google Scholar
89

Golden EB, Apetoh L. Radiotherapy and immunogenic cell death. Semin Radiat Oncol. 2015;25(1):11-17.
Crossref Google Scholar
Precision Radiation Oncology
Volume 7 Issue 2,
June 2023
Pages 128-136
DOI: 10.1002/pro6.1191
Cite this article:
Yan W, Quan C, Mourad WF, et al. Application of radiomics in lung immuno-oncology. Precision Radiation Oncology, 2023, 7(2): 128-136. https://doi.org/10.1002/pro6.1191

250

Views

3

Crossref

3

Scopus

Altmetrics
Received: 19 October 2022
Revised: 22 February 2023
Accepted: 26 February 2023
Published: 04 April 2023
© 2023 The Authors.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Return